Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.35 USD
-0.15 (-1.30%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.36 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.35 USD
-0.15 (-1.30%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.36 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.
Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.
Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.
Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat
by Zacks Equity Research
Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates
by Zacks Equity Research
Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.
Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow
by Zacks Equity Research
Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.
Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. Shares fall.
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.
Dynavax (DVAX) to Report Q3 Earnings: Will It Beat Estimates?
by Zacks Equity Research
On Dynavax's (DVAX) third-quarter earnings call, investors' focus is likely to be on the sales performance of the company's hepatitis B vaccine, HEPLISAV-B.
Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale
by Zacks Equity Research
Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.
Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.
Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why
by Zacks Equity Research
Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.
Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
by Zacks Equity Research
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
by Zacks Equity Research
Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.
Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B
by Zacks Equity Research
Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.
Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study
by Zacks Equity Research
Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.
Wall Street Analysts See an 80.27% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 80.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain
by Zacks Equity Research
Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.
Here's Why Momentum in Dynavax Technologies (DVAX) Should Keep going
by Zacks Equity Research
Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.